Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Breast Neoplasm Female × palbociclib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 96 Neoplasms 11 Neoplasm Metastasis 8 Sarcoma 6 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Melanoma 5 Colorectal Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Squamous Cell Carcinoma of Head and Neck 4 Prostatic Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Lung Neoplasms 4 Leukemia, Myeloid, Acute 4 Multiple Myeloma 3 Liposarcoma 3 Glioblastoma 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Breast Diseases 3 Brain Neoplasms 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Neoplasm, Residual 2 Lymphoma, Non-Hodgkin 2 Inflammation 2 Head and Neck Neoplasms 2 Estrogen Receptor-positive Breast Cancer 2 Esophageal Squamous Cell Carcinoma 2 Chordoma 2

Interventions

venetoclax 1 pyrotinib 1 pertuzumab 1 penpulimab 1 palbociclib 1 dalpiciclib 1 anlotinib 1 Tretinoin 1 Trastuzumab 1 Ropivacaine 1 Radiosurgery 1 Propofol 1 Patient Reported Outcome Measures 1 Paclitaxel 1 Ondansetron 1 Morphine 1 Letrozole 1 Induction Chemotherapy 1 Fulvestrant 1 Etoricoxib 1 Docetaxel 1 Diagnostic Imaging 1 Carboplatin 1 Capecitabine 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03900884 2024-11-07

PALVEN

Peter MacCallum Cancer Centre, Australia

Phase 1 Active not recruiting

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡